Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES.
PROMETHAZINE DM vs TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
1 capsule (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4-6 hours; not to exceed 4 doses in 24 hours.
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Triprolidine: 5-7 hours. Pseudoephedrine: 4-8 hours (pH-dependent; alkaline urine prolongs half-life). Clinical context: Dose adjustment needed in renal impairment for pseudoephedrine.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Triprolidine: Renal excretion of metabolites (approx. 60%) and unchanged drug (less than 5%). Pseudoephedrine: Primarily renal elimination as unchanged drug (70-90%), with minor hepatic metabolism. Fecal excretion is negligible for both.
Category A/B
Category A/B
Antihistamine / Antiemetic
Antihistamine